These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21116322)

  • 21. Rejection and function and chronic allograft dysfunction.
    de Fijter JW
    Kidney Int Suppl; 2010 Dec; (119):S38-41. PubMed ID: 21116316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protecting single-kidney allografts from long-term functional deterioration.
    Remuzzi G; Perico N
    J Am Soc Nephrol; 1998 Jul; 9(7):1321-32. PubMed ID: 9644646
    [No Abstract]   [Full Text] [Related]  

  • 23. Does antihypertensive therapy modify chronic allograft failure?
    Raine AE
    Kidney Int Suppl; 1995 Dec; 52():S107-11. PubMed ID: 8587270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal immunosuppression to prevent chronic allograft dysfunction.
    Grinyó JM; Bestard O; Torras J; Cruzado JM
    Kidney Int Suppl; 2010 Dec; (119):S66-70. PubMed ID: 21116321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and prevention of chronic kidney allograft loss.
    Nankivell BJ; Kuypers DR
    Lancet; 2011 Oct; 378(9800):1428-37. PubMed ID: 22000139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming barriers to long-term graft survival.
    Kaplan B
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S52-64. PubMed ID: 16567241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of early acute rejection episodes to chronic rejection in a rat kidney retransplantation model.
    Tullius SG; Nieminen M; Bechstein WO; Jonas S; Steinmüller T; Qun Y; Pratschke J; Graser E; Sinha P; Volk HD; Neuhaus P; Tilney NL
    Kidney Int; 1998 Feb; 53(2):465-72. PubMed ID: 9461108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
    Kahan BD
    Transplantation; 2001 Jun; 71(11 Suppl):SS52-7. PubMed ID: 11583490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.
    Rosík T; Chadimová M; Dušek J; Háček J; Šimánková N; Vondrák K; Zieg J; Seeman T
    Pediatr Nephrol; 2015 Oct; 30(10):1853-60. PubMed ID: 25925040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of patterns of proteinuria on renal allograft function and survival: a prospective cohort study.
    Suhail SM; Kee TS; Woo KT; Tan HK; Yang WS; Chan CM; Foo MW; Li HH; Siddique MM; Wong KS
    Clin Transplant; 2011; 25(3):E297-303. PubMed ID: 21362048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which antihypertensive drugs are the most nephroprotective and why?
    Cravedi P; Ruggenenti P; Remuzzi G
    Expert Opin Pharmacother; 2010 Nov; 11(16):2651-63. PubMed ID: 20977400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of proteinuria during intensified antihypertensive therapy in children after renal transplantation.
    Seeman T; Simková E; Kreisinger J; Vondrák K; Dusek J; Dvorák P; Stuchlikova H; Janda J
    Transplant Proc; 2007 Dec; 39(10):3150-2. PubMed ID: 18089341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
    Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology and treatment options of chronic renal allograft damage.
    Heemann U; Lutz J
    Nephrol Dial Transplant; 2013 Oct; 28(10):2438-46. PubMed ID: 23625970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance immunosuppressants in the management of antibody-mediated renal allograft rejection: which regimen is best?
    Zhou Y; Li X; Liu Y; Sun Q
    Immunotherapy; 2017 Jan; 9(1):47-55. PubMed ID: 28000532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity in pediatric kidney transplant recipients and the risks of acute rejection, graft loss and death.
    Ladhani M; Lade S; Alexander SI; Baur LA; Clayton PA; McDonald S; Craig JC; Wong G
    Pediatr Nephrol; 2017 Aug; 32(8):1443-1450. PubMed ID: 28361229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretransplant Renal Arterial Vasculopathy of Donor Predicts Poor Renal Allograft Survival.
    Özdemir BH; Özdemir FN; Börcek P; Sercan Ç; Özdemir G; Ayvazoğlu Soy EH; Haberal M
    Exp Clin Transplant; 2018 Mar; 16 Suppl 1(Suppl 1):41-46. PubMed ID: 29527990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.